uniQure NV (NASDAQ:QURE) shares rose 4% during trading on Friday . The company traded as high as $8.59 and last traded at $8.56, with a volume of 108,140 shares trading hands. The stock had previously closed at $8.23.

QURE has been the topic of a number of research analyst reports. Piper Jaffray Cos. reissued a “buy” rating on shares of uniQure NV in a report on Thursday, June 30th. Leerink Swann reissued a “positive” rating and set a $27.00 price target on shares of uniQure NV in a report on Tuesday, August 2nd. HC Wainwright initiated coverage on uniQure NV in a report on Thursday, August 4th. They set a “buy” rating and a $21.00 price target on the stock. Chardan Capital reissued a “buy” rating on shares of uniQure NV in a report on Monday, July 18th. Finally, Zacks Investment Research lowered uniQure NV from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.10.

The firm’s 50-day moving average price is $7.61 and its 200-day moving average price is $11.88. The company’s market capitalization is $212.45 million.

uniQure NV (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.10. Equities research analysts expect that uniQure NV will post ($3.48) earnings per share for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.